Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

20211,519 citationsJournal Articlebronze Open Access

Authors

Good health and well-being

Published in: Journal of Hepatology

Volume 76, Issue 4, pp. 862-873

Field-Weighted Citation Impact: 119.44